The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Total Health

J. Porter

Year in Review: Lung Cancer

Balazs Halmos

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

Current Recommendations on Managing GI Adverse Reactions Associated …

Alberto Zambelli

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Total Health

W. Iams

Perspectives on the Effects of Time Toxicity in Breast Cancer Treatm…

Kathryn Post

J. Hutchinson

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

Mediastinal Staging of Lung Cancer

MI&T Congressi

R. Trisolini

ASCO® 2023 Insights: "ADAURA Trial Key Learnings & Clinical Implicat…

Insights from 2023 ASCO® Annual Meeting

J. West

Oncologists' Perspectives on the Effects of Time Toxicity in Cancer …

Safiya Karim

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

ecancer

L. Raez

2024 Updates on the Fast-Changing NSCLC Landscape

Total Health

R. Osarogiagbon

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

ecancer

E. Felip, A. Spira, A. Passaro, A. Addeo

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles

Year in Review: Precision Medicine

Vivek Subbiah

Controversies in NSCLC: Neoadjuvant vs. Adjuvant IO in Early Stage D…

Luis Raez

Managing Dermatologic Toxicities: Cutaneous irAEs Associated with Im…

Cleveland Clinic Taussig Cancer Institute

R. Unwala

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

E. Rodriguez